Ionis Pharmaceuticals Inc (IONS) stock
IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/304% below fair value
$26.58−0.64 (-2.35%)
Close on Nov 20, 2026Market cap $4.42BP/E –Yield –
Ionis Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Ionis Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$560.84M. For fiscal 2025 it was -$320.03M. The highest annual figure on record is $589.30M in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$320.03M | – |
| FY2024 | Dec 31, 2024 | -$546.23M | – |
| FY2023 | Dec 31, 2023 | -$331.32M | – |
| FY2022 | Dec 31, 2022 | -$290.09M | -1639.4% |
| FY2021 | Dec 31, 2021 | $18.84M | +2340.9% |
| FY2020 | Dec 31, 2020 | $772.00K | -99.8% |
| FY2019 | Dec 31, 2019 | $314.72M | -46.6% |
| FY2018 | Dec 31, 2018 | $589.30M | +322.8% |
| FY2017 | Dec 31, 2017 | $139.39M | – |
| FY2016 | Dec 31, 2016 | -$119.21M | -987.5% |
| FY2015 | Dec 31, 2015 | $13.43M | – |
| FY2014 | Dec 31, 2014 | -$1.23M | -102.0% |
| FY2013 | Dec 31, 2013 | $61.94M | +15502.3% |
| FY2012 | Dec 31, 2012 | $397.00K | – |
| FY2011 | Dec 31, 2011 | -$122.13M | – |
| FY2010 | Dec 31, 2010 | -$76.83M | – |
| FY2009 | Dec 31, 2009 | -$121.86M | -161.4% |
| FY2008 | Dec 31, 2008 | $198.37M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $549.45M | +295.2% |
| Q1 FY2026 | Mar 31, 2026 | -$814.58M | – |
| Q4 FY2025 | Dec 31, 2025 | -$159.00M | – |
| Q3 FY2025 | Sep 30, 2025 | -$136.71M | – |
| Q2 FY2025 | Jun 30, 2025 | $139.03M | – |
| Q1 FY2025 | Mar 31, 2025 | -$163.35M | – |
| Q4 FY2024 | Dec 31, 2024 | -$141.64M | -520.5% |
| Q3 FY2024 | Sep 30, 2024 | -$124.05M | – |
| Q2 FY2024 | Jun 30, 2024 | -$126.11M | – |
| Q1 FY2024 | Mar 31, 2024 | -$154.43M | – |
| Q4 FY2023 | Dec 31, 2023 | $33.68M | – |
| Q3 FY2023 | Sep 30, 2023 | -$111.16M | – |
| Q2 FY2023 | Jun 30, 2023 | -$109.38M | – |
| Q1 FY2023 | Mar 31, 2023 | -$144.46M | – |
| Q4 FY2022 | Dec 31, 2022 | -$204.33M | -201.6% |
| Q3 FY2022 | Sep 30, 2022 | -$29.97M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.43M | – |
| Q1 FY2022 | Mar 31, 2022 | -$34.36M | – |
| Q4 FY2021 | Dec 31, 2021 | $201.19M | +116.7% |
| Q3 FY2021 | Sep 30, 2021 | -$58.90M | – |
| Q2 FY2021 | Jun 30, 2021 | -$67.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$56.43M | – |
| Q4 FY2020 | Dec 31, 2020 | $92.83M | -65.6% |
| Q3 FY2020 | Sep 30, 2020 | -$22.07M | – |
| Q2 FY2020 | Jun 30, 2020 | -$53.32M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.67M | -116.0% |
| Q4 FY2019 | Dec 31, 2019 | $270.08M | +136.7% |
| Q3 FY2019 | Sep 30, 2019 | -$28.71M | – |
| Q2 FY2019 | Jun 30, 2019 | -$31.13M | -106.3% |
| Q1 FY2019 | Mar 31, 2019 | $104.48M | +865.4% |
| Q4 FY2018 | Dec 31, 2018 | $114.12M | +840.1% |
| Q3 FY2018 | Sep 30, 2018 | -$29.25M | -350.6% |
| Q2 FY2018 | Jun 30, 2018 | $493.60M | – |
| Q1 FY2018 | Mar 31, 2018 | $10.82M | -90.9% |
| Q4 FY2017 | Dec 31, 2017 | $12.14M | – |
| Q3 FY2017 | Sep 30, 2017 | $11.67M | -49.8% |
| Q2 FY2017 | Jun 30, 2017 | -$3.85M | – |
| Q1 FY2017 | Mar 31, 2017 | $119.43M | – |
| Q4 FY2016 | Dec 31, 2016 | -$29.63M | – |
| Q3 FY2016 | Sep 30, 2016 | $23.24M | – |
See a number that looks wrong?